Literature DB >> 26514665

Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease.

Victor de Lédinghen1,2, Grace Lai-Hung Wong3,4, Julien Vergniol1, Henry Lik-Yuen Chan3,4, Jean-Baptiste Hiriart1, Anthony Wing-Hung Chan5, Faiza Chermak1, Paul Cheung-Lung Choi5, Juliette Foucher1, Carmen Ka-Man Chan1,2, Wassil Merrouche1, Angel Mei-Ling Chim1,2, Brigitte Le Bail2,6, Vincent Wai-Sun Wong3,4.   

Abstract

BACKGROUND AND AIM: Controlled attenuation parameter (CAP) evaluated with transient elastography (FibroScan) is a recent method for non-invasive assessment of steatosis. Its usefulness in non-alcoholic fatty liver disease (NAFLD) is unknown. We prospectively investigated the performance of CAP for the diagnosis of steatosis in NAFLD, factors associated with discordances between CAP and steatosis grades, and relationships between CAP and clinical or biological parameters.
METHODS: All CAP examinations performed in NAFLD patients with a liver biopsy performed within 1 week of CAP measurement were included. Liver biopsies were assessed for activity and fibrosis stage, NAFLD activity score, and steatosis graded as follows: S0, steatosis < 5%; S1, 5-33%; S2, 34-66%; S3, >66%.
RESULTS: Two hundred sixty-one patients (59% male, age 56 years) from two ethnic groups were included. No patient had steatosis < 5%. The area under the receiver-operating characteristics curve of CAP for steatosis ≥S2 and S3 was 0.80 and 0.66, respectively. At a cut-off value of 310 dB/m, the sensitivity, specificity, and positive and negative predictive values for ≥S2 steatosis were 79%, 71%, 86%, and 71%, respectively. Discordance of at least one grade between CAP and steatosis was observed in 81 patients. By multivariate analysis, only steatosis S2S3 was associated with no discordance. By multivariate analysis, only BMI ≥ 30 kg/m(2) was significantly associated with CAP > 310 dB/m.
CONCLUSION: The association of CAP with steatosis, especially in patients with non-alcoholic steatohepatitis, and with elevated BMI could be useful for the diagnosis and follow-up of NAFLD patients.
© 2015 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  CAP; FibroScan; NAFLD; liver stiffness; metabolic syndrome; obesity; steatosis; transient elastography

Mesh:

Year:  2016        PMID: 26514665     DOI: 10.1111/jgh.13219

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  49 in total

1.  Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Mohammad S Siddiqui; Raj Vuppalanchi; Mark L Van Natta; Erin Hallinan; Kris V Kowdley; Manal Abdelmalek; Brent A Neuschwander-Tetri; Rohit Loomba; Srinivasan Dasarathy; Danielle Brandman; Edward Doo; James A Tonascia; David E Kleiner; Naga Chalasani; Arun J Sanyal
Journal:  Clin Gastroenterol Hepatol       Date:  2018-04-26       Impact factor: 11.382

2.  Quantitative ultrasound and machine learning for assessment of steatohepatitis in a rat model.

Authors:  An Tang; François Destrempes; Siavash Kazemirad; Julian Garcia-Duitama; Bich N Nguyen; Guy Cloutier
Journal:  Eur Radiol       Date:  2018-12-17       Impact factor: 5.315

Review 3.  Clinical advances in pediatric nonalcoholic fatty liver disease.

Authors:  Jeffrey B Schwimmer
Journal:  Hepatology       Date:  2016-03-04       Impact factor: 17.425

Review 4.  Magnetic resonance imaging and transient elastography in the management of Nonalcoholic Fatty Liver Disease (NAFLD).

Authors:  Ma Ai Thanda Han; Rola Saouaf; Walid Ayoub; Tsuyoshi Todo; Edward Mena; Mazen Noureddin
Journal:  Expert Rev Clin Pharmacol       Date:  2017-03-09       Impact factor: 5.045

Review 5.  Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus.

Authors:  Giovanni Targher; Amedeo Lonardo; Christopher D Byrne
Journal:  Nat Rev Endocrinol       Date:  2017-12-29       Impact factor: 43.330

Review 6.  Non-invasive diagnosis of hepatic steatosis.

Authors:  Christiane Stern; Laurent Castera
Journal:  Hepatol Int       Date:  2016-10-25       Impact factor: 6.047

7.  Controlled Attenuation Parameter (CAP) with the XL Probe of the Fibroscan®: A Comparative Study with the M Probe and Liver Biopsy.

Authors:  Victor de Lédinghen; Jean-Baptiste Hiriart; Julien Vergniol; Wassil Merrouche; Pierre Bedossa; Valérie Paradis
Journal:  Dig Dis Sci       Date:  2017-06-02       Impact factor: 3.199

Review 8.  Quantitative Imaging Biomarkers of NAFLD.

Authors:  Sonja Kinner; Scott B Reeder; Takeshi Yokoo
Journal:  Dig Dis Sci       Date:  2016-02-05       Impact factor: 3.199

9.  Risk factors associated with liver steatosis and fibrosis in chronic hepatitis B patient with component of metabolic syndrome.

Authors:  Shaohang Cai; Zejin Ou; Duan Liu; Lili Liu; Ying Liu; Xiaolu Wu; Tao Yu; Jie Peng
Journal:  United European Gastroenterol J       Date:  2018-01-16       Impact factor: 4.623

10.  Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter for the Diagnosis of Liver Steatosis and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease.

Authors:  Sebastian Zenovia; Carol Stanciu; Catalin Sfarti; Ana-Maria Singeap; Camelia Cojocariu; Irina Girleanu; Mihaela Dimache; Stefan Chiriac; Cristina Maria Muzica; Robert Nastasa; Laura Huiban; Tudor Cuciureanu; Anca Trifan
Journal:  Diagnostics (Basel)       Date:  2021-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.